Difference between revisions of "Nivolumab and relatlimab (Opdualag)"
Jump to navigation
Jump to search
m |
|||
| Line 15: | Line 15: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| + | [[Category:Anti-PD-1 antibodies]] | ||
[[Category:Anti-LAG-3 antibodies]] | [[Category:Anti-LAG-3 antibodies]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Combination drugs]] | [[Category:Combination drugs]] | ||
[[Category:FDA approved in 2022]] | [[Category:FDA approved in 2022]] | ||
Revision as of 01:54, 23 March 2022
Mechanism of action
From the NCI Drug Dictionary (for relatlimab): A monoclonal antibody directed against the inhibitor receptor lymphocyte activation gene-3 (LAG-3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, relatlimab binds to LAG-3 on tumor infiltrating lymphocytes (TILs). This may activate antigen-specific T lymphocytes and enhance cytotoxic T cell-mediated tumor cell lysis, which leads to a reduction in tumor growth.
Diseases for which it is used
History of changes in FDA indication
- 3/18/2022: Approved for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. (Based on RELATIVITY-047)
Also known as
- Code name: BMS-986016
- Generic name: nivolumab and relatlimab-rmbw
- Brand name: Opdualag